CL2011000136A1 - Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c. - Google Patents
Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c.Info
- Publication number
- CL2011000136A1 CL2011000136A1 CL2011000136A CL2011000136A CL2011000136A1 CL 2011000136 A1 CL2011000136 A1 CL 2011000136A1 CL 2011000136 A CL2011000136 A CL 2011000136A CL 2011000136 A CL2011000136 A CL 2011000136A CL 2011000136 A1 CL2011000136 A1 CL 2011000136A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- phenylpyridin
- hepatitis
- virus
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de Rna polimerasa dependiente de Rna viral; composición farmacéutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis C.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8284708P | 2008-07-23 | 2008-07-23 | |
US20792509P | 2009-02-17 | 2009-02-17 | |
US17983709P | 2009-05-20 | 2009-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011000136A1 true CL2011000136A1 (es) | 2011-07-08 |
Family
ID=41057595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000136A CL2011000136A1 (es) | 2008-07-23 | 2011-01-21 | Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c. |
Country Status (18)
Country | Link |
---|---|
US (1) | US8273773B2 (es) |
EP (1) | EP2307372B1 (es) |
JP (1) | JP2011528686A (es) |
KR (1) | KR20110033291A (es) |
CN (1) | CN102099335A (es) |
AR (1) | AR072824A1 (es) |
AT (1) | ATE555096T1 (es) |
AU (1) | AU2009273327A1 (es) |
BR (1) | BRPI0916233A2 (es) |
CA (1) | CA2730517A1 (es) |
CL (1) | CL2011000136A1 (es) |
ES (1) | ES2383273T3 (es) |
IL (1) | IL209696A0 (es) |
MX (1) | MX2011000656A (es) |
PE (1) | PE20110409A1 (es) |
TW (1) | TW201008922A (es) |
WO (1) | WO2010010017A1 (es) |
ZA (1) | ZA201009183B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010002904A (es) | 2007-09-17 | 2010-06-02 | Abbott Lab | N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv). |
ATE519746T1 (de) | 2007-09-17 | 2011-08-15 | Abbott Lab | Antiinfektiöse pyrimidine und anwendungen davon |
SG183733A1 (en) | 2007-09-17 | 2012-09-27 | Abbott Lab | Uracil or thymine derivative for treating hepatitis c |
JP2012503620A (ja) * | 2008-09-26 | 2012-02-09 | エフ.ホフマン−ラ ロシュ アーゲー | Hcvを処置するためのピリンまたはピラジン誘導体 |
CN102186823A (zh) * | 2008-10-30 | 2011-09-14 | 弗·哈夫曼-拉罗切有限公司 | 杂环类抗病毒芳基吡啶酮衍生物 |
KR20110122874A (ko) * | 2009-03-06 | 2011-11-11 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
CN102361858B (zh) * | 2009-03-24 | 2014-07-23 | 艾伯维巴哈马有限公司 | 制备抗病毒化合物的方法 |
WO2010111436A2 (en) * | 2009-03-25 | 2010-09-30 | Abbott Laboratories | Antiviral compounds and uses thereof |
SG175774A1 (en) * | 2009-04-25 | 2011-12-29 | Hoffmann La Roche | Heterocyclic antiviral compounds |
BRPI1010900A2 (pt) * | 2009-05-20 | 2016-03-15 | Hoffmann La Roche | compostos antivirais heterocíclicos |
MX2012001653A (es) * | 2009-08-07 | 2012-06-19 | Hoffmann La Roche | Derivado de aminopirazol. |
AU2010297290A1 (en) * | 2009-09-21 | 2012-03-15 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
WO2011061243A1 (en) * | 2009-11-21 | 2011-05-26 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
KR101893751B1 (ko) | 2010-07-16 | 2018-09-03 | 애브비 아일랜드 언리미티드 컴퍼니 | 항바이러스성 화합물의 제조 방법 |
US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
BR112013001138A2 (pt) | 2010-07-16 | 2016-07-05 | Abbvie Inc | ligantes de fosfina para reações catalíticas |
US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
JP5620417B2 (ja) * | 2011-02-07 | 2014-11-05 | 中外製薬株式会社 | アミノピラゾール誘導体を含む医薬 |
NO2686520T3 (es) | 2011-06-06 | 2018-03-17 | ||
TW201329025A (zh) | 2011-11-01 | 2013-07-16 | Astex Therapeutics Ltd | 醫藥化合物 |
KR102073445B1 (ko) | 2012-07-31 | 2020-02-04 | 다우 글로벌 테크놀로지스 엘엘씨 | 올레핀 중합 촉매 활성화제의 제조 방법 |
WO2014095555A1 (en) | 2012-12-19 | 2014-06-26 | Basf Se | New substituted triazoles and imidazoles and their use as fungicides |
PT3007695T (pt) | 2013-06-13 | 2024-03-07 | Akebia Therapeutics Inc | Composições e métodos para tratamento de anemia |
WO2015016295A1 (ja) | 2013-07-31 | 2015-02-05 | 中外製薬株式会社 | アミノピラゾール誘導体含有医薬品製剤 |
DK3080134T3 (en) * | 2013-12-13 | 2018-10-22 | Vertex Pharma | PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS |
WO2015099127A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬 |
CA2974691A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
IL292262B2 (en) | 2015-04-01 | 2024-02-01 | Akebia Therapeutics Inc | Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid |
US10479780B2 (en) | 2015-06-17 | 2019-11-19 | Chugai Seiyaku Kabushiki Kaisha | Aminopyrazole derivatives |
AU2019265629A1 (en) | 2018-05-09 | 2021-01-07 | Akebia Therapeutics, Inc. | Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid |
CN110724091B (zh) * | 2019-12-04 | 2022-03-11 | 阿里生物新材料(常州)有限公司 | 一种6-(二氟甲基)-2-羟基吡啶-3-磺酰氯的合成方法 |
CN112876409A (zh) * | 2021-01-20 | 2021-06-01 | 都创(上海)医药科技股份有限公司 | 一种2-(5-溴-6-甲氧基吡啶-2-基)乙腈及其衍生物的合成方法 |
CN112898200A (zh) * | 2021-01-20 | 2021-06-04 | 都创(上海)医药科技股份有限公司 | 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
AU2001261377A1 (en) | 2000-05-10 | 2001-11-20 | Smith Kline Beecham Corporation | Novel anti-infectives |
MXPA05004670A (es) * | 2002-11-01 | 2005-08-18 | Abbott Lab | Agentes anti-infecciones. |
US20040097492A1 (en) | 2002-11-01 | 2004-05-20 | Pratt John K | Anti-infective agents |
EP1794172B1 (en) * | 2004-08-23 | 2009-07-15 | F.Hoffmann-La Roche Ag | Antiviral 4'-azido-nucleosides |
AU2007339386B8 (en) * | 2006-12-22 | 2013-12-05 | Merck Sharp & Dohme Corp. | 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections |
BRPI0816116A2 (pt) | 2007-08-29 | 2015-03-03 | Schering Corp | Derivados de indol 2,3-substituídos para o tratamento de infecções virais. |
TW200911807A (en) | 2007-08-29 | 2009-03-16 | Schering Corp | 2,3-substituted azaindole derivatives and methods of use thereof |
AU2008295483B2 (en) | 2007-08-29 | 2013-11-21 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
ATE519746T1 (de) | 2007-09-17 | 2011-08-15 | Abbott Lab | Antiinfektiöse pyrimidine und anwendungen davon |
MX2010002904A (es) | 2007-09-17 | 2010-06-02 | Abbott Lab | N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv). |
SG183733A1 (en) | 2007-09-17 | 2012-09-27 | Abbott Lab | Uracil or thymine derivative for treating hepatitis c |
CA2705587A1 (en) | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
JP5249344B2 (ja) | 2007-11-16 | 2013-07-31 | メルク・シャープ・アンド・ドーム・コーポレーション | ヘテロ環の3位が置換されたインドール誘導体およびその使用 |
WO2010111436A2 (en) | 2009-03-25 | 2010-09-30 | Abbott Laboratories | Antiviral compounds and uses thereof |
RU2552533C2 (ru) | 2009-03-25 | 2015-06-10 | Эббви Инк. | Противовирусные соединения и их применения |
-
2009
- 2009-07-15 CN CN2009801283861A patent/CN102099335A/zh active Pending
- 2009-07-15 BR BRPI0916233A patent/BRPI0916233A2/pt not_active IP Right Cessation
- 2009-07-15 EP EP09780611A patent/EP2307372B1/en not_active Not-in-force
- 2009-07-15 WO PCT/EP2009/059039 patent/WO2010010017A1/en active Application Filing
- 2009-07-15 PE PE2011000046A patent/PE20110409A1/es not_active Application Discontinuation
- 2009-07-15 AU AU2009273327A patent/AU2009273327A1/en not_active Abandoned
- 2009-07-15 JP JP2011519125A patent/JP2011528686A/ja active Pending
- 2009-07-15 MX MX2011000656A patent/MX2011000656A/es not_active Application Discontinuation
- 2009-07-15 KR KR1020117003937A patent/KR20110033291A/ko not_active Application Discontinuation
- 2009-07-15 ES ES09780611T patent/ES2383273T3/es active Active
- 2009-07-15 AT AT09780611T patent/ATE555096T1/de active
- 2009-07-15 CA CA2730517A patent/CA2730517A1/en not_active Abandoned
- 2009-07-20 AR ARP090102751A patent/AR072824A1/es unknown
- 2009-07-22 US US12/460,658 patent/US8273773B2/en not_active Expired - Fee Related
- 2009-07-22 TW TW098124765A patent/TW201008922A/zh unknown
-
2010
- 2010-12-01 IL IL209696A patent/IL209696A0/en unknown
- 2010-12-21 ZA ZA2010/09183A patent/ZA201009183B/en unknown
-
2011
- 2011-01-21 CL CL2011000136A patent/CL2011000136A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2307372A1 (en) | 2011-04-13 |
MX2011000656A (es) | 2011-02-23 |
ZA201009183B (en) | 2013-05-29 |
ES2383273T3 (es) | 2012-06-19 |
WO2010010017A1 (en) | 2010-01-28 |
US8273773B2 (en) | 2012-09-25 |
ATE555096T1 (de) | 2012-05-15 |
CN102099335A (zh) | 2011-06-15 |
BRPI0916233A2 (pt) | 2018-03-13 |
JP2011528686A (ja) | 2011-11-24 |
AU2009273327A1 (en) | 2010-01-28 |
TW201008922A (en) | 2010-03-01 |
EP2307372B1 (en) | 2012-04-25 |
US20100021423A1 (en) | 2010-01-28 |
AR072824A1 (es) | 2010-09-22 |
PE20110409A1 (es) | 2011-06-22 |
IL209696A0 (en) | 2011-02-28 |
KR20110033291A (ko) | 2011-03-30 |
CA2730517A1 (en) | 2010-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011000136A1 (es) | Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c. | |
CL2009000305A1 (es) | Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv). | |
CL2008003511A1 (es) | Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
CL2007003250A1 (es) | Compuestos derivados de isoquinolina, inhibidores del virus de hepatitis c; composicion farmaceutica; y uso para el tratamiento de una infeccion por vhc. | |
CL2007003299A1 (es) | Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
CL2008001005A1 (es) | Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv. | |
BRPI1013394A2 (pt) | "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c." | |
CL2011002453A1 (es) | Compuestos derivados de diazol u oxazol-pirrol o pirrolciclopropil condensados sustituidos, inhibidores de la función de la proteína ns5a codificada por el virus de la hepatitis c (vhc); composición farmacéutica; y su uso para el tratamiento de una infección por vhc. | |
CL2012002489A1 (es) | Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c. | |
CL2009002207A1 (es) | Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c. | |
UY32717A (es) | Inhibidores de la replicación de virus de la gripe | |
CL2011002082A1 (es) | Composicion farmaceutica que comprende un inhibidor de nucleosido polimerasa y un inhibidor de proteasa macrociclica; proceso para preparar dicha composicion farmaceutica; metodo para tratar o mejorar una infeccion con virus de la hepatitis c, fibrosis hepatica y alteracion de la funcion hepatica. | |
CL2012001176A1 (es) | Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv. | |
CL2011001364A1 (es) | Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv). | |
CL2012000573A1 (es) | Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv. | |
CL2013001141A1 (es) | Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c. | |
CL2011000558A1 (es) | Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c. | |
CL2011001224A1 (es) | Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c. | |
CL2007002284A1 (es) | Compuestos derivados de tetrazolilos macrociclicos; proceso de preparacion; composicion farmaceutica; y uso para tratar una infeccion viral de hepatitis c. | |
CL2014001641A1 (es) | Compuestos derivados de nucleosidos sustituidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y uso para mejorar o tratar una infeccion viral. | |
CL2012001959A1 (es) | Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae. | |
CL2013003360A1 (es) | “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct | |
CL2011002830A1 (es) | Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c. | |
CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. | |
CL2014001599A1 (es) | Compuestos derivados de nucleosidos sustituidos en 4’-azido, 3’-fluoro o sus sales, como inhibidores de la replicacion del rna del vhc; composicion farmaceutica que los comprende; y su uso para el tratamiento o la profilaxis de la infeccion por el virus de la hepatitis c (vhc). |